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To examine the association between potentially modifiable risk factors with cardiovascular
disease (CVD) and all-cause mortality and to quantify their population attributable fractions
(PAFs) among a sample of Tehran residents.
Methods
Overall, 8108 participants (3686 men) aged30 years, were investigated. To examine the
association between risk factors and outcomes, multivariate sex-adjusted Cox proportional
hazard regression analysis were conducted, using age as time-scale in two models includ-
ing general/central adiposity: 1)adjusted for different independent variables including smok-
ing, education, family history of CVD and sex for both outcomes and additionally adjusted
for prevalent CVD for all-cause mortality 2)further adjusted for obesity mediators (hyperten-
sion, diabetes, lipid profile and chronic kidney disease). Separate models were used includ-
ing either general or central adiposity.
Results
During median follow-up of >10 years, 827 first CVD events and 551 deaths occurred. Both
being overweight (hazard ratio (HR), 95%CI: 1.41, 1.18–1.66, PAF 13.66) and obese (1.51,
1.24–1.84, PAF 9.79) played significant roles for incident CVD in the absence of obesity
mediators. Predicting CVD, in the presence of general adiposity and its mediators, signifi-
cant positive associations were found for hypercholesterolemia (1.59, 1.36–1.85, PAF
16.69), low HDL-C (1.21, 1.03–1.41, PAF 12.32), diabetes (1.86, 1.57–2.27, PAF 13.87),
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hypertension (1.79, 1.46–2.19, PAF 21.62) and current smoking (1.61, 1.34–1.94, PAF
7.57). Central adiposity remained a significant positive predictor, even after controlling for
mediators (1.17, 1.01–1.35, PAF 7.55). For all-cause mortality, general/central obesity did
not have any risk even in the absence of obesity mediators. Predictors including diabetes
(2.56, 2.08–3.16, PAF 24.37), hypertension (1.43, 1.11–1.84, PAF 17.13), current smoking
(1.75, 1.38–2.22, PAF 7.71), and low education level (1.59, 1.01–2.51, PAF 27.08) were
associated with higher risk, however, hypertriglyceridemia (0.83, 0.68–1.01) and being over-
weight (0.71, 0.58–0.87) were associated with lower risk.
Conclusions
Modifiable risk factors account for more than 70% risk for both CVD and mortality events.
Introduction
Cardiovascular diseases (CVD) are the leading cause of both mortality and disability world-
wide [1]. Approximately, two-thirds (63%) of premature deaths in adults (aged 15–69 years),
and three-out-of-four of all adult deaths are attributable to non-communicable diseases, which
are mainly due to CVD [2]. It has been predicted that by 2030, over 23.3 million people will
die annually from CVD [3], most of which will occur in low-and-middle income countries,
such as those in Middle East, where rapid changes in lifestyle, ageing populations and trans-
forming environments all contribute to the dramatic pace of the epidemic [4]. It has been
shown that CVDs are becoming a major health problem in this region mostly due to the
already high and fast increasing prevalence of cardiovascular risk factors [5–11]. In spite of
having higher CVD morbidity and mortality; compared to Western countries, data in regards
to the dynamics of CVD from Eastern population is limited [12].
Management of the multiple modifiable risk factors associated with incident CVD and all-
cause mortality in the general populations is an ongoing challenge for primary health care
decision makers. Population attributable fraction (PAF), a measure of potential global impact,
is one of the most applicable indices in public health which can assist policymakers in prioritiz-
ing health strategies among the general population [13]. It is the hypothetical reduction in inci-
dence that would be observed if the population were entirely unexposed, compared with its
current (actual) exposure pattern [13].
The aim of the current study is to determine the associations of potentially modifiable car-
diovascular risk factors including general or central obesity, smoking, educational level, blood
pressure categories, glucose intolerance status, lipid profile and chronic kidney disease (CKD)
with CVD and all-cause mortality and their PAF, using data from a long-term population–
based prospective study, the Tehran Lipid-Glucose Study (TLGS), with over a decade long fol-
low-up.
Methods and Materials
Study design and sample
The Tehran Lipid and Glucose Study (TLGS) is an ongoing prospective population-based
study performed on a representative sample of the Tehran population, aimed at determining
the prevalence and incidence of non-communicable diseases and their risk factors. Details of
Risk Factors for Incident CVD and All-Cause Mortality and Their PAF; TLGS
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the TLGS have been reported elsewhere [14]. In brief, one baseline examination (1999–2001)
and 3 follow-up phases at about 3-year intervals had been carried out until 2012.
Study population
Exclusions were carried out at two separate lines for all-cause mortality and CVD event analy-
sis. For all-cause mortality analysis, from among 9752 participants (5331 women and 4421
men)30 years [7550 people from the baseline examination (1999–2001) and 1597 new par-
ticipants were recruited from the second phase (2001–2005)], after exclusions of 705 cases
with missing data on any examined baseline variables and 939 participants with no follow-up
from baseline examination; finally 8108 participants (4422 women and 3686 men) remained to
be followed till 2012, (mean follow-up of 10.67 years and 3.88 interquartile range, response
rate 83%) (Fig 1).
For CVD event analysis, among 9752 participants aged 30 years or more were selected. Sub-
jects with prevalent CVD on baseline examination (N = 605), missing data (N = 668) or with-
out any follow-up (N = 844) were excluded, leaving 7635 participants (4205 women and 3430
men) for the current study, who were followed up till 2012 (mean follow-up of 10.73 years and
3.65 interquartile range, response rate 83%) (Fig 1).
A written consent was obtained from all participants after being informed about the general
aspects of the investigation and the study protocol conforms to the ethical guidelines of the
1975 Declaration of Helsinki as reflected in prior approval by the ethical committee of the
Research Institute for Endocrine Sciences (RIES).
Clinical and laboratory measurements
Using a standard questionnaire, a trained interviewer collected information, which included
demographic data, drug history and family history of type 2 diabetes (T2D) and CVD. Details
of anthropometric measurements including weight, height and waist circumference (WC), sys-
tolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements have been
reported elsewhere (14).
A blood sample was taken between 7:00 and 9:00 AM from all study participants, after 12 to
14 hours overnight fasting. Details of laboratory measurement including fasting plasma glucose
Fig 1. Study population.
doi:10.1371/journal.pone.0167623.g001
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(FPG), total cholesterol (TC), triglyceride (TG) and high-density lipoprotein (HDL-C) were
reported elsewhere (14).
Glomerular filtration rate (GFR) was estimated using the abbreviated prediction equa-
tion, provided by the Modification of Diet in Renal Disease (MDRD) study as follows:
GFR ¼ 186 ðSCrÞ  1:145  ðAgeÞ  0:203  ð0:742 if femaleÞ  ð1:210 if African   AmericanÞ
In this equation, estimated GFR (eGFR) is expressed as mL/min per 1.73 m2 and serum
creatinine (Scr) as mg/dL [15].
Definition of terms and outcomes measurement
Cardiovascular risk factors were categorized and defined as illustrated in Table 1. For a collec-
tion of cardiovascular outcomes, each participant has followed up annually for any medical
event; a trained nurse asked them regarding any related medical condition, and a trained phy-
sician collected complementary data for that event, during a home visit, and also by the acqui-
sition of data from medical files from hospitals and any medical encounters. In the current
study, the events targeted were the first CVD event, including definite myocardial infarction
(MI), probable MI, unstable angina, angiographic-proven CHD, and stroke (defined by a new
neurological deficit that lasted more than 24 h). In case of mortality, data were collected by an
authorized local physician from the hospital or the death certificate. Data collected were evalu-
ated by an outcome committee (Cohort Outcome Panel) consisting of a principal investigator,
an internist, an endocrinologist, a cardiologist, an epidemiologist, and the physician who col-
lected the outcome data; other experts were invited as required for evaluation of non-commu-
nicable disorders. The final diagnosis was by consensus of the majority of committee members
(i.e. by3 members of the committee).
Statistical analysis
Baseline characteristics of the study population are presented as mean or frequency (percent-
age) for continuous and categorical variables, respectively.
All possible first-order interactions between sex and independent variables were checked in
multivariable analysis (i.e. sex × BMI, sex × glucose intolerance status, sex × WC, sex × blood
pressure categories, sex × TC, sex × HDL-C, sex× TG, sex × family history of CVD, sex × smok-
ing, sex × education levels, sex × CKD, sex × prevalent CVD). Considering the Bonferroni cor-
rection as a multiple comparison correction, we found no P value 0.01 for interaction between
different risk factors with sex for either CVD or mortality events [22]; hence, we adjusted for sex,
to reach full statistical power, in the different models. Similarly, we also found no interaction
between prevalent CVD and different risk factors for mortality events (all P-values for interac-
tions>0.01). All of the interactions were tested by log-likelihood ratio test.
Cox proportional hazard models with age as the time scale [23], were used to estimate the
hazard ratios (HRs) with 95% confidence intervals (95% CIs) of different risk factors for devel-
opment of each outcome of interest in two models including general/central obesity adjusted
for 1) different independent variables including smoking, education, family history of CVD
and sex for both outcomes and additionally adjusted for prevalent CVD for all-cause mortality,
2) the above risk factors plus obesity mediators including blood pressure categories, glucose
intolerance status, abnormal lipid profile (hypercholesterolemia, low HDL-C, and hypertrigly-
ceridemia) [24] and chronic kidney disease (CKD) [25–28], applying the enter method. Non-
modifiable risk factors including sex, family history of CVD and prevalent CVD were consid-
ered as confounder variables in our data analysis. To overcome the issue of collinearity, we
conducted separate models for general and central adiposity.
Risk Factors for Incident CVD and All-Cause Mortality and Their PAF; TLGS
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The proportional hazard assumption was examined using Schoenfeld residuals test and
plotting log [–log (survival)] versus log (time) to assess parallelism. Follow-up duration was
defined as the period between entrance to study and the end point; end points were considered
as the first CVD event or mortality, and censoring was defined as leaving the residence area,
lost to follow-up or until the end of the study.





HRadj indicates multivariate-adjusted hazard ratio for a particular exposure factor and Pc
represents the prevalence of that exposure among individuals with the outcome of interest.
Table 1. Definition of different cardiovascular risk factors categories; Tehran Lipid and Glucose
Study 1999–2012
CVD risk factor Definition
Glucose intolerance
Non-diabetic FPG< 100mg/dl (5.55 mmol/l) and 2h-PCPG<140 mg/dl (7.77 mmol/l) and taking
no anti-diabetic medications
Diabetic[16] FPG126 mg/dl (7 mmol/l) or 2 h-PCPG200 mg/dl (11.1 mmol/l) or taking any
medication for T2D
Pre-diabetic[17] Individuals who were not characterized as non-diabetic or diabetic
General obesity
Normal BMI BMI<25 kg/m2
Overweight 25 BMI<30 kg/m2
Obese BMI 30 kg/m2
Central obesity Waist circumference95 cm [18]
Blood pressure [19]
Normotensive SBP <120 mmHg and DBP <80 mmHg
Hypertension SBP140 mmHg or DBP90 mmHg or taking any medication for hypertension
Pre-hypertensive Individuals who were not characterized as normotensive or hypertensive
Dyslipidemia [20]
Hypercholesterolemia TC 6.21 mmol/L or using lipid lowering medications
Hypertriglyceridemia TG 1.69 mmol/L
Low HDL-C HDL-C< 1.06 mmol/L (men) or HDL-C<1.29 mmol/L (women)
Family history of
CVD
History of myocardial infarction, stroke or sudden cardiac death in a male first
degree relative <55 years or in a female first degree relative <65
Current smoking Participants who used any tobacco product (cigarette, pipe, and water pipe) at
time of examination
Education
<6 Illiterate participant and those with primary school education or less (less than 6
years of education)
6–12 Those who had a diploma or did not complete the diploma but finished the primary
school (6 years)
>12 Those with higher than diploma education(more than 12 years of education)
CKD Those with eGFR<60 mL/min/1.73 m2[21].
FPG, Fasting plasma glucose; 2h-PCPG, 2 hour-post-challenge plasma glucose; BMI, body mass index;
T2D, type 2 diabetes; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG,
triglycerides; HDL-C, high-density lipoprotein cholesterol; CKD, chronic kidney disease; eGFR, estimated
glomerular filtration rate.
doi:10.1371/journal.pone.0167623.t001
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Stata (Stata Corp 12 SE) was used for data analysis and p values<0.05 were considered statisti-
cally significant. Additionally, to recover our missing data, we used multivariate imputation by
chained equation, using a regression including all of the variables in the main models [30, 31].
Results
The study sample for analysis of all-cause mortality consisted of 8108 participants, aged30
years, mean age 47.52 (range 30–88 years). Baseline characteristics of respondent and non-
respondent participants (those with missing data at the baseline or with no follow-up data) in
our sample are shown in Table 2. Compared to non-respondents, respondents were older,
more educated and hypercholesterolemic and had higher WC; however, they had lower BMI,
the rates of current smoking as well as prevalent CVD. Aforementioned results were similar in
study sample for CVD events (n = 7635).
During the follow-up period, 827 first CVD events and 551 deaths occurred. Underlying
causes of mortality were CVD (n = 255), cancer (n = 89), sepsis and pneumonia (n = 48),
accidents (n = 19), other heart diseases (n = 23), diabetes complications (n = 18), unknown
(n = 53) and miscellaneous reasons (n = 46).
Multivariate-adjusted hazard ratios and 95% confidence intervals (CIs) of potential cardio-
vascular risk factors as well as their PAFs for incident CVD and all-cause mortality, controlled
for BMI and in the absence of obesity mediators are shown in Table 3. Accordingly, both
being overweight (HR, 95% CI: 1.41, 1.18–1.66) and obese (1.51, 1.24–1.84) played significant
roles for in a higher risk of incident CVD. Furthermore, there were significant positive associa-
tions between family history of CVD, smoking and male gender with CVD events. Further-
more, smoking, less than 6 years of education, family history of CVD, male gender, and
prevalent CVD remained significant predictors for higher risk of mortality. Our results
showed that being overweight was associated with lower risk of mortality events (0.8, 0.66–
0.97, P = 0.030).
Multivariate-adjusted hazard ratios and 95% confidence intervals (CIs) of potential cardio-
vascular risk factors as well as their PAFs for incident CVD and all-cause mortality, controlled
for BMI and in the presence of obesity mediators are shown in Table 4. Accordingly, signifi-
cant positive associations between hypercholesterolemia, low HDL-C level, hypertension, dia-
betes, current smoking, family history of CVD, male gender, and incident CVD were observed
(all p values< 0.05). Predicting all-cause mortality, hypertension (1.43, 1.11–1.84), diabetes
(2.56, 2.08–3.16) smoking (1.75, 1.38–2.22), less than 6 years of education (1.59, 1.01–2.51),
male gender (1.48, 1.21–1.82), prevalent CVD (1.63, 1.32–2.02), family history of CVD (1.24,
0.99–1.55, P = 0.054) revealed positive associations with higher risk of death. However, general
obesity (0.79, 0.62-.1.00, P = 0.058), being overweight (0.71, 0.58-.87, P = 0.001) and hypertri-
glyceridemia (0.83, 68–1.01; P = 0.066) were associated with lower risks of all-cause mortality.
PAFs calculations, in CVD event analysis, showed that hypertension had the highest popu-
lation attributed risk (21.62%) followed by hypercholesterolemia (16.69%), diabetes (13.87%),
low HDL-C (12.32%) and smoking (7.57%). As for all-cause mortality, having less than 6 years
of education had the highest attributed risk (27.08%), followed by diabetes (24.37%), hyperten-
sion (17.13%), prevalent CVD (8.12%) and smoking (7.71).
Multivariate-adjusted hazard ratios and 95% confidence intervals (95% CIs) of potential
cardiovascular risk factors as well as their PAFs for incident CVD and all-cause mortality, con-
trolled for central adiposity and in the absence and presence of obesity mediators are shown in
Tables A and B in S1 File, respectively. Results were generally as same as those observed in the
presence of general adiposity; however, in contrast to general adiposity, abdominal obesity had
a significant association with CVD, in the presence of mediators (1.17, 1.01–1.35).
Risk Factors for Incident CVD and All-Cause Mortality and Their PAF; TLGS
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Table 2. Baseline characteristics* of respondent and non-respondent participants in both genders; Tehran Lipid and Glucose Study 1999–2005.
Respondent (n = 8108) Non-respondent (n = 1644) P-value†
Continuous variables: Mean (SD) Mean (SD)
Age (years) ** 47.52(12.44) 48.30(13.96) 0.025
BMI (kg/m2) 27.52(4.56) 27.18(4.74) 0.012
Waist circumference (cm) 90.87(11.53) 89.87(11.52) 0.004
Triglyceride levels (mmol/L) 2.06(1.34) 2.12(1.68) 0.170
Total cholesterol (mmol/L) 5.53(1.18) 5.57(1.22) 0.226
HDL-C (mmol/L) 1.07(0.28) 1.08(0.29) 0.066
Systolic blood pressure (mmHg) 121.69(19.96) 122.37(21.13) 0.239
Diastolic blood pressure (mmHg) 78.64(11.03) 78.68(11.06) 0.900
Fasting plasma glucose (mmol/L) 5.62(1.96) 5.67(2.29) 0.331
eGFR (mL/min/1.73 m2) 68.89(11.54) 68.03(12.55) 0.018
Categorical variables††:
Sex(men) 3686(45.46) 735(44.71) 0.576
General obesity
Normal BMI 2424(29.90) 437(26.58) 0.076
Overweight 3524(43.46) 579(35.22)
Obese 2160(26.64) 326(19.83)
Central obesity 3047(37.58) 466(28.35) 0.057
Hypertriglyceridemia 4328(53.38) 693(42.15) 0.109
Hypercholesterolemia 2248(27.73) 423(25.73) 0.015
Low HDL-C 5701(70.31) 958(58.27) 0.442
Blood Pressure
Normal 3279(40.44) 564(34.31) 0.728
Pre hypertension 2679(33.04) 481(29.26)
Hypertension 2150(26.52) 389(23.66)
Blood Sugar Status
Non-diabetic 5096(62.85) 680(41.4) 0.003
Pre-diabetic 1862(22.97) 266(16.2)
Diabetic 1150(14.18) 205(12.5)
CKD** 1698(20.94) 327(19.89) 0.09
Current smoking 1356(16.72) 299(18.18) <0.0001
Education status
>12 years 988(12.19) 186(11.31) 0.022
6–12 years 3789(46.73) 713(43.37)
<6 years 3331(41.08) 729(44.34)
Family history of CVD 1358(16.75) 255(15.51) 0.618
Anti-hypertensive drug 776(9.57) 171(10.40) 0.300
Anti-diabetic drugs 447(5.51) 90(5.47) 0.950
Lipid lowering drugs 327(4.03) 82(4.99) 0.078
Prevalent CVD 472(5.82) 133(8.09) 0.001
* Baseline characteristics were reported by frequency (percent) in each category and compared by Chi-square test otherwise indicated.
** Age was reported by mean (SD) in each group and compared by Student’s independent t-test.
† P-values were derived from comparison between respondent and non-respondent participants
††for categorical variables, numbers (percent), the definition of categorical variables is shown in Table 1.
eGFR, glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; CKD, chronic kidney disease.
doi:10.1371/journal.pone.0167623.t002
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The results of imputation analysis were similar to our main results (Tables C-J in S1 File).
Discussion
Using data from a 10-year follow-up of an Iranian adult population, we estimated the associa-
tion of potential cardiovascular risk factors as well as their PAFs for incident CVD and all-
cause mortality rate. To the best of our knowledge, this is the first study conducted in the Mid-
dle East region, reporting the population attributable fraction of potential risk factors for inci-
dent CVD and all-cause mortality. Considering CVD event, in the absence of obesity
mediators, general obesity, being overweight and high WC was associated with higher CVD
incidence. Additionally, in the presence of mediators, hypercholesterolemia, low HDL-C,
hypertension, diabetes, and smoking were attributed to higher CVD event rate. Central obe-
sity, per se, in the presence of obesity mediators, had an independent positive association with
CVD incidence. Considering all-cause mortality, although significant positive associations
were observed for hypertension, diabetes, smoking and low education level; hypertriglyceride-
mia was inversely associated. Modifiable risk factors including hypertension, diabetes, smok-
ing (for both CVD and mortality events), plus hypercholesteremia and low HDL-C (for CVD)
and low education level (for mortality events) accounted for more than 70% of the PAF of
both outcomes.
General and central obesity which are commonly assessed with BMI and WC respectively
were associated with higher risk of incident CVD and all-cause mortality [32, 33]. In the cur-
rent study, only in the absence of obesity mediators, being overweight and obesity showed sig-
nificant risk for CVD events and whereas all together they showed a PAF of about 23%.
However, in our data analysis, it has been indicated that the detrimental effect of general obe-
sity on CVD event was mediated by hypertension, T2D and serum lipid profile. A pooled anal-
ysis of 97 prospective cohorts with 1.8 million participants, showed almost over 50% of the
Table 3. Multivariate-adjusted hazard ratios and 95% confidence intervals (CIs) of potential cardiovascular risk factors for incident CVD and all-
cause mortality, without obesity mediators controlling for general adiposity status, Tehran lipid and Glucose study (1999–2012)



















Normal 1 0.24 0.21–0.27 - 1 0.36 0.31–0.39 -
Overweight 1.41 1.18–1.66 <0.0001 0.47 0.43–0.50 13.66 6.55–19.87 0.80 0.66–0.97 0.030 0.39 0.35–0.43 -9.75 (-18.03)-
(-1.32)
Obesity 1.51 1.24–1.84 <0.0001 0.29 0.25–0.32 9.79 4.83–14.60 0.98 0.77–1.23 0.878 0.25 0.21–0.29 -
Current
Smoker
1.53 1.27–1.83 <0.0001 0.20 0.17–0.23 6.92 3.61–10.43 1.63 1.29–2.06 <0.0001 0.18 0.14–0.21 6.95 3.14–10.80
Education
>12 years 1 1 0.05 0.02–0.06 -
6–12 years 1.22 0.92–1.62 0.159 - 1.49 0.94–2.38 0.088 0.22 0.19–0.26 7.23 (-1.21)-
15.07
<6 years 1.16 0.87–1.55 0.295 - 1.67 1.06–2.63 0.027 0.73 0.69–0.77 29.28 3.90–47.72
Family history
of CVD




1.73 1.47–2.02 <0.0001 - 1.42 1.17–1.73 <0.0001 -
Prevalent CVD - 2.01 1.62–2.47 <0.0001 0.21 0.17–0.21 10.55 6.50–12.49
*Prevalence represents the prevalence of the exposure among individuals with outcome of interest
**The population attributed fractions were calculated using the following formula: Prevalence*((Hazard ratio-1)/Hazard ratio)
HR, hazard ratio; HDL-C, high-density lipoprotein cholesterol; CKD, chronic kidney disease
The definition of categorical variables is shown in Table 1.
doi:10.1371/journal.pone.0167623.t003
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excess risk for CVD was mediated through three metabolic risk factors which can be explained
as obesity mediators i.e. blood pressure categories, glucose intolerance status, abnormal lipid
profile [24]. Furthermore, studies showed that obesity is associated with an increased inci-
dence of CKD [25, 26] and CKD, per se, plays a role as an independent predictor of MI, stroke,
and death [27, 28]. Hence, we added CKD as another obesity mediator.
In line with other studies [34–36], we showed that central adiposity was associated with
higher risk of incident CVD. A finding which indicated that, in contrast to BMI, in the pres-
ence of obesity mediators, WC, per se, increased the risk of CVD incidence. In several large-
scale studies, WC was found to be one of the most important predictors of CVD [37–39]. Cer-
han.et al, also reported higher WC in both genders to be associated with higher mortality at all
levels of BMI between 20–50 kg/m2 [34]; their finding supports the importance and major role
of central obesity over general obesity in predicting incident CVD; which also was highlighted
in other publications[40, 41]. On the other hand, for all-cause mortality, consistent with sev-
eral studies, our results are supportive of the well-known “obesity paradox” [42–44]. We found
that compared to normal BMI participants, overweight and obsess individuals had over 20%
decreased risk for all-cause mortality. It has been shown that there is a U-shaped association
between BMI and all-cause mortality with the concave regions sitting in the region of BMI
22–27 kg/m2[45]; this U-shaped relationship might be a result of the fact that BMI is composed
of different components, i.e. fat mass, and fat-free mass, which have opposite effects on mortal-
ity, i.e. in contrast to fat mass, fat-free mass has an inverse association with mortality [46]. Fur-
thermore, in a recent meta-analysis, overweight and moderately obese participants had lower
mortality compared to normal BMI participants [33]. The authors concluded that use of prede-
fined standard BMI groupings can facilitate between-study comparisons. Hence in the current
study, we applied standard cutoffs for categorization of general adiposity. It should also be consid-
ered that over half of obese subjects in our population had grade 1 obesity (30–35 kg/m2) (Data
not shown). Possible explanations include the earlier presentation of illness in overweight/obese
population, greater likelihood of receiving optimal medical treatment, the cardio-protective meta-
bolic effects of increased body fat, having better nutrition status and benefits of higher metabolic
reserves [47]. It also should be considered in our study, following CVD, cancer and sepsis were
the most common causes of death and weight loss is one of the most well-known poor prognostic
factors in patients with both malignant and inflammatory diseases [48–50].
In line with previous studies, we observed both incident CVD and all-cause mortality to be
increased among participants with diabetes [51–53]. Generally, diabetes is a prevalent meta-
bolic disorder among Iranians [54] and is known as a coronary heart disease equivalent [55].
In the light of the high incidence and PAF of diabetes in this population [56], greater fraction
of CVD and mortality event rates are expected to be attributable to diabetes in the future.
Similar to previous studies, we showed that hypertension is an independent, putative risk
factor for incident CVD and all-cause mortality [57] and reduction in hypertension incidence
remarkably reduces the risk of incident CVD and all-cause. In fact, hypertension is known as
the most important modifiable risk factor for CVD and all-cause mortality worldwide [58, 59].
Therefore, more aggressive efforts may help decrease CVD risk and mortality among those
already affected by inadequately treated or untreated hypertension.
More than 7% of incident CVD and of all-cause mortality were attributable to smoking in
our study sample. Compared to current literature which reported smoking to be responsible for
approximately 12% and 6% of male and female deaths respectively, worldwide [60, 61]. Recent
studies also show that smoking in Iranian populations has an experiencing increasing trend [10,
62, 63]; this coupled with the fact that in Iran, unlike developed countries, smoking cessation
counseling services are infrequently available or actively offered by health professionals.
Risk Factors for Incident CVD and All-Cause Mortality and Their PAF; TLGS
PLOS ONE | DOI:10.1371/journal.pone.0167623 December 8, 2016 10 / 16
It has been reported that even smoking a few cigarettes during childhood are associated
with significantly higher odds of daily smoking in adolescence [64]. The prevalence of 15%
was reported for current smoking in a study conducted among Iranian male high school ado-
lescents [65]. However, unfortunately, we have no data in our study sample about the initiation
trend of smoking and amount of tobacco use during childhood. Our findings showed that pri-
oritization of smoking controlling programs at national levels to be effective strategies for the
prevention of CVD and premature death.
Considering dyslipidemia, in the current study, hypercholesterolemia and low HDL-C, all
together, account for about 30% of PAF of incident CVD. The significant roles of hypercholester-
olemia and low HDL-C as well-established risk factors for incident CVD have been highlighted
before[66]. Treatment of elevated cholesterol and mixed lipid disorders using statins may relieve
some of the burden, as recently noted for patients with diabetes and stroke[66]. Despite the fact
that the lipid-lowering drugs consumption in our population has increased remarkably (1.59 vs.
6% within a decade)[10], almost one-third of our population with dyslipidemia have not achieved
the target levels of lipid measures may be due to poor compliance [10]. We also observed a favor-
able time trends in the population levels of lipid profile including HDL-C during 10 years follow-
up [11].
One intriguing result reached through our study was that high serum TG was inversely
associated with all-cause mortality among participants. Recently, we showed that 1 SD incre-
ment in log-transformed TGs was accompanied with 19% lower risk of non-CVD mortality
[67]. A contention in contrast with previous studies, which highlighted the linear relation
between hypertriglyceridemia and mortality [68, 69]; one explanation would be that low TG
could be a marker of malnutrition and weight loss which, in turn, may increase mortality risk
in the population [70]. In our study, after CVD, cancer was the most common cause of death
and it has been shown that the low TG and weight loss are poor prognostic signs in cancerous
patients and are associated with poor survival [48–50, 71]. Recently, we showed that hypertri-
glyceridemic waist circumference increased the age-adjusted risk of incident CVD, among
both men and women [72]. Noticeably, in previous studies, we detected favorable time trends
in the population levels of TG in the TLGS population (from 2.11 to 1.94 mmol/L in men and
from 1.88 to 1.74 mmol/L in women) [11]; this significant decrease in TG levels could be the
other plausible justification to this intriguing result.
Importantly, lower education level potentially increased the risk of all-cause mortality by
about 60% and showed the highest PAF of 27% among other risk factors. A steady relationship
documented between mortality and educational inequalities indicated that higher education
status is associated with better adaptation to preventive lifestyles, lower prevalence of risk fac-
tors, early diagnosis and management of chronic disease risk factors, better quality treatment
of acute diseases and lower risk of malnutrition and infection [73]. In line with our findings,
Yusuf et al. found that nine easily measured and potentially modifiable risk factors such as
education level account for an overwhelmingly large (over 90%) proportion of the risk of an
initial acute myocardial infarction [74].
The strengths of our study include the prospective nature, the use of a large population-
based-cohort of both sexes, accurate and valid data on risk factors at baseline and continuous
surveillance of mortality, based on standard criteria. Our findings, however, need to be inter-
preted in the light of our study limitations. First, the population studied was of Persian ances-
try, because of which, our results might not be directly extrapolated to other populations.
Second, we only considered the status of risk factors at baseline and did not consider changes
during the long-term follow-up. Third, we did not have enough statistical power to investigate
the impact of risk factors for cause-specific mortality events. Fourth, we also used PAF as an
epidemiologic tool to quantify the burden of CVD and mortality attributable to modifiable
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risk factors. This guides policymakers in prioritizing health strategies and interventions. In
fact, PAF is a theoretical concept, and total elimination of certain risk factors by conducting
intervention programs at the population level is generally almost impossible. In this regard,
PAF is a better tool for prioritization than attributable risk. In most epidemiological studies,
PAF measures only the excess fraction (the proportion of cases developing over some period
of time among the exposed population, i.e. “excess” in comparison with the unexposed), rather
than etiologic fraction (the proportion of cases in which the exposure has a causal role in dis-
ease occurrence) [75]. Last but not least, in a population-based observational cohort study of
TLGS, the extent and importance of the risk factors are highlighted and the effect of treatment,
interventions and the impact of different methods for accomplishing the changes shall be
tested in clinical trial settings.
Conclusion
Among modifiable risk factors, we found positive associations between diabetes, hypertension,
current smoking and both outcomes; hypercholesterolemia, low HDL-C and CVD incidence;
low education level and all-cause mortality events. These potentially modifiable risk factors
which account for over 70% risk for both CVD and mortality events, indicating that modifica-
tion of derived risk factors has the potential to prevent most CVD/all-cause mortality events
among Tehranian adults.
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